Netherton syndrome: Successful use of topical tacrolimus and pimecrolimus in four siblings

International Journal of Dermatology

Volumn 46, Issue 3, 2007, Pages 290-294

  Saif, Ghada Bin ^a   Al Khenaizan, Sultan ^a  

^a KING FAHAD NATIONAL GUARD HOSPITAL   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE DIPROPIONATE; CALCINEURIN INHIBITOR; FLUTICASONE PROPIONATE; HYDROCORTISONE; IMMUNOGLOBULIN E; MOMETASONE FUROATE; PERDERM; PETROLATUM; PIMECROLIMUS; PROGAF; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ARTICLE; ATOPY; AUTOSOMAL RECESSIVE DISORDER; CASE REPORT; CHILD; DRUG BLOOD LEVEL; EOSINOPHILIA; FEMALE; HAIR DISEASE; HUMAN; ICHTHYOSIS; INFANT; MALE; NETHERTON DISEASE; RASH; SAUDI ARABIA; SKIN DISEASE; TRICHORRHEXIS;

ADMINISTRATION, TOPICAL; CHILD; CHILD, PRESCHOOL; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HAIR; HUMANS; ICHTHYOSIS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; REMISSION INDUCTION; SYNDROME; TACROLIMUS;

EID: 33847775240     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2006.02956.x     Document Type: Article

References (50)

1. Netherton EW. A unique case of trichorrhexis nodosa; bamboo hairs. Arch Dermatol 1958; 78: 483-487.
2. DiGiovanna JJ. Ichthyosiform dermatoses: So many discoveries, so little progress. J Am Acad Dermatol 2004; 51: S31-S34.
3. Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: Atopic dermatitis and beyond. Int J Clin Pract 2005; 59: 969-974.
4. Allen DM, Esterly NB. Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Arch Dermatol 2002; 138: 1259-1260.
5. Allen A, Siegfried E, Silverman R, et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001; 137: 747-750.
6. Bens G, Boralevi F, Buzenet C, et al. Topical treatment of Netherton's Syndrome with tacrolimus ointment without significant systemic absorption. Br J Dermatol 2003; 149: 224-226.
7. Sybert VP. Disorders of the epidermis. In: Sybert VP, ed. Genetic Skin Disorders. New York, Oxford: Oxford University Press, 1997: 5-128.
8. Greene SL, Muller SA. Netherton's syndrome. Report of a case and review of the literature. J Am Acad Dermatol 1985; 13: 329-337.
9. Caputo R, Vanotti P, Bertani E. Netherton's syndrome in two adult brothers. Arch Dermatol 1984; 120: 220-222.
10. Brodin MB, Porter PS. Netherton's syndrome. Cutis 1980; 26: 185-188, 191.
11. Kassis V, Nielsen JM, Klem-Thomsen H, et al. Familial Netherton's disease. Cutis 1986; 38: 175-178.
12. Stankler L, Cochrane T. Netherton's disease in two sisters. Br J Dermatol 1967; 79: 187-196.
13. Plantin P, Delaire P, Guillet MH, et al. Netherton's syndrome. Current aspects. Apropos of 9 cases. Ann Dermatol Venereol 1991; 118: 525-530.
14. Wehr RF, Hickman J, Krochmal L. Effective treatment of Netherton's syndrome with 12% lactate lotion. J Am Acad Dermatol 1988; 19: 140-142.
15. Hausser I, Anton-Lamprecht I. Severe congenital generalized exfoliative erythroderma in newborns and infants: A possible sign of Netherton syndrome. Pediatr Dermatol 1996; 13: 183-199.
16. Judge MR, Morgan G, Harper JI. A clinical and immunological study of Netherton's syndrome. Br J Dermatol 1994; 131: 615-621.
17. Curth HO. Netherton's syndrome and ichthyosis linearis circumflexa. Arch Dermatol 1970; 101: 485.
18. Jones SK, Thomason LM, Surbrugg SK, et al. Neonatal hypernatraemia in two siblings with Netherton's syndrome. Br J Dermatol 1986; 114: 741-743.
19. Salamon T, Lazovic O, Stenek S. The Netherton Syndrome. Hautarzt 1972; 23: 66-71.
20. Stryk S, Siegfried EC, Knutsen AP. Selective antibody deficiency to bacterial polysaccharide antigens in patients with Netherton syndrome. Pediatr Dermatol 1999; 16: 19-22.
21. Ansai S, Mitsuhashi Y, Sasaki K. Netherton's syndrome in siblings. Br J Dermatol 1999; 141: 1097-1100.
22. Chavanas S, Garner C, Bodemer C, et al. Localization of the Netherton syndrome gene to chromosome 5q32, by linkage analysis and homozygosity mapping. Am J Hum Genet 2000; 66: 914-921.
23. Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000; 25: 141-142.
24. Bitoun E, Bodemer C, Amiel J, et al. Prenatal diagnosis of a lethal form of Netherton syndrome by SPINK5 mutation analysis. Prenat Diagn 2002; 22: 121-126.
25. Bitoun E, Chavanas S, Irvine AD, et al. Netherton syndrome: Disease expression and spectrum of SPINK5 mutations in 21 families. J Invest Dermatol 2002; 118: 352-361.
26. Magert HJ, Standker L, Kreutzmann P, et al. LEKTI, A novel 15-domain type of human serine proteinase inhibitor. J Biol Chem 1999; 274: 21499-21502.
27. Sprecher E, Chavanas S, DiGiovanna JJ, et al. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: Implications for mutation detection and first case of prenatal diagnosis. J Invest Dermatol 2001; 117: 179-187.
28. Raghunath M, Tontsidou L, Oji V, et al. SPINK5 and Netherton Syndrome: novel mutations, demonstration of missing LEKTI, and differential expression of transglutaminases. J Invest Dermatol 2004; 123: 474-483.
29. Suga Y, Tsuboi R, Hashimoto Y, et al. A case of Ichthyosis linearis circumflexa successfully treated with topical tacrolimus. J Am Acad Dermatol 2000; 42: 520-522.
30. Borzyskowski M, Grant DB, Wells RS. Cushing's syndrome induced by topical steroids used for the treatment of non-bullous ichthyosiform erythroderma. Clin Exp Dermatol 1976; 1: 337-342.
31. Traupe H, Happle R. Etretinate therapy in children with severe keratinization defects. Eur J Pediatr 1985; 143: 66-69.
32. Hausser I, Anton-Lamprecht I, Hartschuh W, et al. Netherton's syndrome: ultrastructure of the active lesion under retinoid therapy. Arch Dermatol Res 1989; 281: 165-172.
33. Godic A, Dragos V. Successful treatment of Netherton's syndrome with topical calcipotriol. Eur J Dermatol 2004; 14: 115-117.
34. Nagata T. Netherton's syndrome which responded to photochemotherapy. Dermatologica 1980; 161: 51-56.
35. Braun RP, Ramelet AA. Failure of cyclosporine in Netherton's Syndrome. Dermatology 1997; 195: 75.
36. Buxman M, Hickman J, Ragsdale W, et al. Therapeutic activity of lactate 12% lotion in the treatment of ichthyosis. Active versus vehicle and active versus a petrolatum cream. J Am Acad Dermatol 1986; 15: 1253-1258.
37. Smith DL, Smith JG, Wong SW, et al. Netherton's syndrome: A syndrome of elevated IgE and characteristic skin and hair findings. J Allergy Clin Immunol 1995; 95: 116-123.
38. Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: Mechanisms of action. Eur J Dermatol 2002; 12: 618-622.
39. Gupta AK, Adamiak A, Chow M. Tacrolimus: A review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol 2002; 16: 100-114.
40. Grassberger M, Steinhoff M, Schneider D, et al. Pimecrolimus an anti-inflammatory drug targeting the skin. Exp Dermatol 2004; 13: 721-730.
41. Graham-Brown RA, Grassberger M. Pimecrolimus: A review of pre-clinical and clinical data. Int J Clin Pract 2003; 57: 319-327.
42. Hoetzenecker W, Meingassner JG, Ecker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol 2004; 122: 673-684.
43. Kalthoff FS, Chung J, Musser P, et al. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003; 133: 350-359.
44. Panhans-Gross A, Novak N, Kraft S, et al. Human epidermal Langerhans'cells are targets for the immunosuppressive macrolide tacrolimus (FK506). J Allergy Clin Immunol 2001; 107: 345-352.
45. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: A randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-513.
46. Billich A, Aschauer H, Aszòdi A, et al. Percutaneous absorption of drugs used in atopic eczema: Pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharmacol 2004; 269: 29-35.
47. Ruzicka T, Assmann T, Homey B. Tacrolimus: The drug for the turn of the millennium? Arch Dermatol 1999; 135: 574-580.
48. Mrowietz U, Wustlich S, Hoexter G, et al. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol 2003; 83: 351-353.
49. Beljan G, Traupe H, Metze D, et al. Comel-Netherton syndrome with bacterial super infection. Hautarzt 2003; 54: 1198-1202.
50. Oji V, Beljan G, Beier K, et al. Topical pimecrolimus: A novel therapeutic option for Netherton syndrome. Br J Dermatol 2005; 153: 1067-1068.